Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.

摘要: Objective To assess safety and efficacy of infliximab in patients with ankylosing spondylitis (AS) through 102 weeks. Methods Patients (n = 279) active AS were randomized to either group 1 78; placebo week 24 then 5 mg/kg from weeks 96) or 2 201; 96). The primary end point at (≥20% improvement the ASsessment Ankylosing Spondylitis International Working Group criteria [ASAS20]) was assessed an intent-to-treat analysis observed data. Results More than achieved ASAS20 response (61.2% versus 19.2%; P < 0.001). By 102, groups similar regard (72.1% 73.9%); ASAS40 responses 45.9% 59.4%. No new issues discerned. Conclusion Infliximab demonstrated sustained over years this large cohort AS.